B Cell Lymphoma
SAN DIEGO—A phase 1 study suggests lymphodepletion can improve the efficacy of CD30-directed chimeric antigen receptor (CAR) T-cell therapy in...
SAN DIEGO—A recurrent mutation in BCL2, the therapeutic target of venetoclax, appears to be a major contributor to drug resistance in patients...
PF-05280586 showed biosimilarity to rituximab at up to 26 weeks in a randomized phase 3 study of treatment-naive patients with CD20-positive LTB-...
SAN DIEGO – The mutation was present only after therapy in paired samples from patients enrolled in clinical trials of venetoclax.
SAN DIEGO—A shortened regimen of four cycles of rituximab (R) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy...
SAN DIEGO—A newly approved treatment regimen provides a survival benefit over standard therapy for patients with CD30-positive peripheral T-cell...
SAN DIEGO—An updated analysis of the JULIET trial showed that tisagenlecleucel produced a high rate of durable responses in adults with relapsed...
SAN DIEGO – Median overall survival among patients with complete responses to CAR-T cell therapy in the JULIET trial has not been reached.
SAN DIEGO – Median overall survival for patients with complete responses to CAR T-cell therapy was not reached through 19 months of follow-up.